NCT06664814

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2026-06-14Est. Completion: 2027-11-30

Enrollment target: 30 participants

Locations

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Contact

Proteinuric Kidney Diseases

This study is open to adults with certain kidney conditions, including secondary focal segmental glomerulosclerosis (sFS…

Huntsville, United StatesEst. completion Jan 20, 2028

Focal Segmental GlomerulosclerosisGlomerulonephritis Minimal Lesion

This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis …

Birmingham, United StatesEst. completion Dec 23, 2026

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.